Skip to content

Randomised trial, 2021

Does ulipristal acetate (a progesterone blocker) treat PMDD?

Yes. Women taking 5 mg daily improved by 41% versus 22% on placebo. Half achieved remission with the medication compared to 21.1% on placebo.

Strong study design 95 women with PMDD

What they did

95 women with PMDD took either 5 mg daily of ulipristal acetate or placebo during three 28-day treatment cycles. They recorded symptoms daily using a smartphone app. The main measure was change in total symptom scores.

What they found

The ulipristal acetate group improved by 41% on overall symptoms compared to 22% in the placebo group. For depression symptoms, improvement was 42% versus 22%. For anger and irritability, improvement was 47% versus 23%. Half of the ulipristal acetate group (50%) achieved remission compared to 21.1% of the placebo group. The medication did not significantly help physical symptoms.

What it means for you

This is a promising result for treating PMDD, especially mood symptoms. The main limits are that the study was relatively small and only lasted three 28-day cycles, so longer follow-up and larger studies are needed to confirm this works. The medication did not help physical symptoms as much as mood symptoms.

95

Women in study

41%

Improvement on treatment

50%

Remission rate with treatment

About the study

Original title
Ulipristal Acetate for Treatment of Premenstrual Dysphoric Disorder: A Proof-of-Concept Randomized Controlled Trial
Authors
Comasco E, Kopp Kallner H, Bixo M et al.
Journal
The American journal of psychiatry
Year
2021
Study design
Randomised trial
Participants
95
What was tested
Ulipristal acetate 5 mg daily

Topics